TY - BOOK ID - 145152812 TI - Cancer Immunology AU - Subramanian, Subree AU - Zhao, Xianda PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Medicine KW - NKG2D KW - CAR T KW - IL-7 KW - prostate cancer KW - cell therapy KW - CD19-CAR-T KW - B cell aplasia KW - KIR KW - PD-1 KW - inhibitory CAR KW - tumor-infiltrating lymphocytes KW - tumor microenvironment KW - immunotherapy KW - NK cells KW - cancer stem cells (CSCs) KW - antibody-dependent cellular cytotoxicity (ADCC) KW - differentiation KW - cytotoxicity KW - IFN-γ KW - osteoclasts KW - MICA/B mAb KW - DNA methylation KW - RNA methylation KW - S-adenosylmethionine (SAM) KW - cancer KW - innate immunity KW - adaptive immunity KW - T cells KW - m6A KW - PD-L1 KW - resistance KW - immune checkpoints KW - cancer vaccine KW - combination immunotherapy KW - TCR diversity KW - organ transplantation KW - carcinoma KW - epidemiologic studies KW - immunosuppression KW - CTLA-4 KW - Treg cells KW - immune checkpoint inhibitors KW - CD28 KW - antigen-presenting cells KW - IL15 KW - colon cancer KW - melanoma KW - uveal KW - BAP1 KW - anti-PD-1 KW - anti-CTLA-4 KW - TIL KW - classical and endemic Kaposi Sarcoma KW - systemic treatment KW - multi-state modelling KW - treatment free interval KW - chemotherapy KW - interferon KW - triple negative breast cancer KW - immunomodulation KW - bispecific antibody KW - sortase A KW - chemo-enzymatic approach KW - anti-CD20 antibody KW - Fab KW - BiFab KW - colorectal cancer KW - dendritic cells KW - Atypical Chemokine Receptor 4 (ACKR4) KW - T-cell priming KW - immune checkpoint blockade KW - primary liver cancer KW - kynurenine pathway KW - immune evasion KW - indoleamine 2,3 dioxygenase 1 KW - tryptophan 2,3 dioxygenase 2 KW - IDO inhibitor KW - antigen presenting cells UR - https://www.unicat.be/uniCat?func=search&query=sysid:145152812 AB - The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue. ER -